Overall, ASTN treatment inhibits HFD-induced NASH progression by impairing the progression of liver fibrosis, suppressing oxidative stress, and modulating intrahepatic immune response (Figure 8). Here, ASTN1 is linked to metabolic dysfunction-associated steatohepatitis.